scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1090448725 |
P356 | DOI | 10.1038/S41541-017-0021-9 |
P8608 | Fatcat ID | release_vlzgrbtirjhylecbqn26wyenne |
P932 | PMC publication ID | 5627234 |
P698 | PubMed publication ID | 29167748 |
P50 | author | Nandadeva Lokugamage | Q117812116 |
Tetsuro Ikegami | Q40311693 | ||
P2860 | cites work | VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION * | Q22255613 |
Viral mutation rates | Q24611162 | ||
Rift Valley fever virus NSs protein functions and the similarity to other bunyavirus NSs proteins | Q26745530 | ||
The impact of regulations, safety considerations and physical limitations on research progress at maximum biocontainment | Q26830833 | ||
Homologous recombination in negative sense RNA viruses | Q27024104 | ||
Complete Genome Analysis of 33 Ecologically and Biologically Diverse Rift Valley Fever Virus Strains Reveals Widespread Virus Movement and Low Genetic Diversity due to Recent Common Ancestry | Q27478367 | ||
The use of veterinary vaccines for prevention and control of Rift Valley fever: memorandum from a WHO/FAO meeting | Q27486846 | ||
RNA polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent Rift Valley fever viruses | Q27487321 | ||
Safety and Efficacy Profile of Commercial Veterinary Vaccines against Rift Valley Fever: A Review Study | Q28066283 | ||
Body temperature of C57BL/6J mice with age | Q71352791 | ||
Live attenuated vaccines: Historical successes and current challenges | Q28082036 | ||
Characterization of Rift Valley fever virus MP-12 strain encoding NSs of Punta Toro virus or sandfly fever Sicilian virus | Q28486276 | ||
Reversion of Cold-Adapted Live Attenuated Influenza Vaccine into a Pathogenic Virus | Q30390811 | ||
Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines | Q30502375 | ||
TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus. | Q33198557 | ||
A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells. | Q33316823 | ||
Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics | Q33357041 | ||
Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation | Q33406230 | ||
Challenges and Practices in Building and Implementing Biosafety and Biosecurity Programs to Enable Basic and Translational Research with Select Agents. | Q33699916 | ||
Altered virulence of vaccine strains of measles virus after prolonged replication in human tissue. | Q33821235 | ||
Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus | Q33877518 | ||
Host alternation is necessary to maintain the genome stability of rift valley fever virus | Q33918307 | ||
Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention | Q33960690 | ||
An investigation of a major outbreak of Rift Valley fever in Kenya: 2006-2007 | Q34034053 | ||
History of vaccination | Q34119899 | ||
Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep | Q34221766 | ||
Attenuated vaccines can recombine to form virulent field viruses | Q34288335 | ||
Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments. | Q34475358 | ||
Dual functions of Rift Valley fever virus NSs protein: inhibition of host mRNA transcription and post-transcriptional downregulation of protein kinase PKR. | Q35107614 | ||
Molecular epidemiology of Rift Valley fever virus | Q35849036 | ||
Evaluation of the Efficacy, Potential for Vector Transmission, and Duration of Immunity of MP-12, an Attenuated Rift Valley Fever Virus Vaccine Candidate, in Sheep. | Q35902010 | ||
The dominant-negative inhibition of double-stranded RNA-dependent protein kinase PKR increases the efficacy of Rift Valley fever virus MP-12 vaccine | Q36155392 | ||
Genetic subpopulations of Rift Valley fever virus strains ZH548 and MP-12 and recombinant MP-12 strains | Q36414512 | ||
Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates. | Q36514844 | ||
The L, M, and S Segments of Rift Valley Fever Virus MP-12 Vaccine Independently Contribute to a Temperature-Sensitive Phenotype | Q36694012 | ||
Toscana virus NSs protein promotes degradation of double-stranded RNA-dependent protein kinase | Q36759758 | ||
Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis | Q36916391 | ||
Rift Valley fever virus MP-12 vaccine encoding Toscana virus NSs retains neuroinvasiveness in mice | Q37006803 | ||
Mutational Analysis of the Rift Valley Fever Virus Glycoprotein Precursor Proteins for Gn Protein Expression. | Q37049951 | ||
Quantitative modeling of virus evolutionary dynamics and adaptation in serial passages using empirically inferred fitness landscapes | Q37547542 | ||
Vaccines in veterinary medicine: a brief review of history and technology | Q37752963 | ||
The double-edged sword: How evolution can make or break a live-attenuated virus vaccine | Q37999021 | ||
The role of mutational robustness in RNA virus evolution | Q38092577 | ||
Designing cell lines for viral vaccine production: Where do we stand? | Q38436738 | ||
Vaccination of alpacas against Rift Valley fever virus: Safety, immunogenicity and pathogenicity of MP-12 vaccine. | Q39066685 | ||
NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase | Q39195523 | ||
The Rift Valley fever epizootic in Egypt 1977–1978 1. Description of the epizootic and virological studies | Q39240187 | ||
Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs | Q39601913 | ||
Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study. | Q39778317 | ||
Recombination between vaccine and field strains of canine parvovirus is revealed by isolation of virus in canine and feline cell cultures | Q39898767 | ||
T7 RNA polymerase-dependent and -independent systems for cDNA-based rescue of Rift Valley fever virus | Q39946457 | ||
NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription | Q39960501 | ||
Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans. | Q40124756 | ||
Comparative efficacy of two next-generation Rift Valley fever vaccines | Q40199478 | ||
Evaluation of lamb and calf responses to Rift Valley fever MP-12 vaccination | Q40206211 | ||
Evolutionary transition toward defective RNAs that are infectious by complementation. | Q40213221 | ||
Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins | Q40233812 | ||
Rescue of infectious rift valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene | Q40311587 | ||
Genetic evidence for Rift Valley fever outbreaks in Madagascar resulting from virus introductions from the East African mainland rather than enzootic maintenance | Q40327417 | ||
Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys | Q40557158 | ||
Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. | Q40579610 | ||
Improved Recovery of Rabies Virus from Cloned cDNA Using a Vaccinia Virus‐Free Reverse Genetics System | Q40629273 | ||
Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. | Q40632227 | ||
Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids | Q40645618 | ||
Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle | Q40645625 | ||
Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. | Q40679919 | ||
Ability of a mutagenized virus variant to protect young lambs from Rift Valley fever | Q40753140 | ||
Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep | Q40753243 | ||
Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes | Q40795447 | ||
Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development | Q40814834 | ||
Regulatory considerations for emergency use of non-USDA licensed vaccines in the United States. | Q42033084 | ||
Homologous recombination is apparent in infectious bursal disease virus | Q43730394 | ||
Tempering the risk: Rift Valley fever and bioterrorism | Q44936397 | ||
Characterization of a rare natural intertypic type 2/type 3 penta-recombinant vaccine-derived poliovirus isolated from a child with acute flaccid paralysis. | Q48067438 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P921 | main subject | Rift Valley fever | Q326638 |
Rift Valley fever virus | Q14276794 | ||
Rift Valley fever phlebovirus | Q24809101 | ||
P577 | publication date | 2017-07-17 | |
P1433 | published in | NPJ Vaccines | Q30275609 |
P1476 | title | Genetic stability of Rift Valley fever virus MP-12 vaccine during serial passages in culture cells | |
P478 | volume | 2 |
Q92503441 | Evolution of Attenuation and Risk of Reversal in Peste des Petits Ruminants Vaccine Strain Nigeria 75/1 |
Q59351098 | Molecular aspects of Rift Valley fever virus and the emergence of reassortants |
Q92812197 | Population- and Variant-Based Genome Analyses of Viruses from Vaccine-Derived Rabies Cases Demonstrate Product Specific Clusters and Unique Patterns |
Search more.